Global Spatial Transcriptomics Sequencing Supply, Demand and Key Producers, 2026-2032

September 2026 | 139 pages | ID: GE6C1E15A7DDEN
GlobalInfoResearch

Abstracts

The global Spatial Transcriptomics Sequencing market size is expected to reach $ 274 million by 2032, rising at a market growth of 8.5% CAGR during the forecast period (2026-2032).

Spatial transcriptomics sequencing is an advanced molecular biology technique that combines the principles of transcriptomics (the study of the complete set of RNA transcripts in a cell or tissue) with spatial information. It enables the simultaneous measurement of gene expression levels and the determination of the location of those transcripts within a tissue sample. By preserving the spatial context of gene expression, this technology provides a more comprehensive understanding of how genes are expressed in different regions of a tissue, which is crucial for elucidating complex biological processes, disease mechanisms, and cellular interactions. It typically involves methods to capture and sequence RNA molecules directly from specific locations within a tissue section, followed by computational analysis to map the gene expression data back to their spatial coordinates.

Key Findings

• Spatial Transcriptomics Sequencing links gene-expression measurements with native tissue architecture and cellular location
• NGS-Based Capture Spatial Transcriptomics supports broad transcriptome profiling across spatially barcoded tissue areas
• In Situ Sequencing-Based Spatial Transcriptomics emphasizes single-cell or subcellular localization and high-plex molecular imaging
• Cancer Research Developmental Biology and Neuroscience form the principal application framework of the market

Market Trends

Spatial Transcriptomics Sequencing is progressing toward higher spatial resolution, broader transcript coverage, larger tissue capture areas and more integrated multiomic analysis. Sequencing-based systems are narrowing the historical trade-off between whole-transcriptome breadth and cellular-level localization through denser spatial features, improved barcoding chemistry and scalable sequencing workflows. In situ platforms are simultaneously increasing gene-panel size, imaging area, acquisition speed and compatibility with RNA and protein measurements in the same tissue section. Support for formalin-fixed paraffin-embedded samples is becoming increasingly important because it enables researchers to access archived clinical specimens and connect spatial information with established histopathology. The workflow is also shifting from instrument- or assay-centered purchasing toward complete sample-to-insight solutions combining tissue handling, reagents, sequencing or imaging, data processing, cell segmentation, visualization and biological interpretation. As datasets become larger, computational efficiency, interoperability and standardized quality-control metrics are becoming as important as molecular sensitivity. Longer term, the industry is moving toward reproducible cohort-scale studies, spatial multiomics, three-dimensional tissue reconstruction and closer integration with single-cell sequencing, digital pathology and artificial intelligence-assisted image analysis.

Market Dynamics

Drivers

The principal driver of Spatial Transcriptomics Sequencing is the need to understand biological heterogeneity without losing tissue context. Conventional bulk RNA sequencing averages signals across many cells, while dissociative single-cell methods provide cell-level expression profiles but separate cells from their original locations. Spatial workflows connect molecular states with tumor regions, neural structures, developmental compartments and neighboring cell populations, supporting more detailed analysis of cell interactions and tissue organization. Cancer researchers use the technology to investigate tumor microenvironments, immune-cell distribution, clonal organization and treatment-related changes. Developmental Biology studies use spatial maps to examine organ formation, cell-fate transitions and temporal patterning, while Neuroscience applications benefit from the ability to associate molecularly defined cell types with anatomical regions and neural circuits. Continued investment in genomics, precision medicine, biomarker research and tissue-atlas programs therefore expands the potential customer base across universities, medical centers, pharmaceutical companies and biotechnology developers.

Restraints

Spatial Transcriptomics Sequencing remains technically and economically demanding because results are highly sensitive to tissue quality, sectioning, fixation, permeabilization, staining, probe performance and experimental design. Some workflows require expensive dedicated instruments, proprietary consumables and high-capacity sequencing or imaging infrastructure, limiting adoption by laboratories with irregular sample volumes. Whole-transcriptome assays can generate substantial sequencing, storage and computational requirements, whereas targeted in situ methods require prior selection of genes and may miss unexpected biological signals outside the panel. Differences in spatial resolution, capture efficiency, tissue area, transcript sensitivity and cell-segmentation methodology also make direct comparison among platforms difficult. Sample preparation protocols may need optimization for different organs, species and preservation methods, and unsuccessful tissue processing can result in the loss of scarce clinical material. These factors increase the importance of experienced laboratory personnel and often encourage smaller research groups to outsource projects rather than establish complete internal workflows.

Opportunities

Major opportunities are developing around archived clinical tissue, spatial multiomics, large-cohort research and specialized sequencing services. Greater compatibility with formalin-fixed paraffin-embedded samples can unlock extensive pathology archives for retrospective Cancer Research and translational biomarker programs. Combining spatial RNA measurements with proteins, morphology, genomic alterations or other molecular layers can provide a more complete representation of cell states and tissue interactions than transcript analysis alone. Service providers can expand demand by offering integrated tissue assessment, experimental design, sectioning, staining, assay execution, sequencing, imaging, bioinformatics and biological interpretation, thereby lowering technical barriers for laboratories without dedicated spatial infrastructure. New opportunities also arise from cross-species studies, organoids, regenerative biology, drug-response mapping and preclinical model characterization. Suppliers capable of improving throughput and workflow standardization may support a transition from small exploratory experiments to larger cohort studies and pharmaceutical research programs.

Challenges

The industry must address reproducibility, analytical standardization and biological interpretation as Spatial Transcriptomics Sequencing moves into larger and more decision-relevant studies. Tissue morphology, RNA integrity, capture chemistry, imaging quality, sequencing depth and computational parameters can each influence the final spatial map. Cell segmentation is particularly important for cellular and subcellular workflows because incorrect boundaries can assign transcripts to the wrong cell and distort cell-type or interaction analysis. Batch effects arising from different slides, instruments, laboratories or sample-processing dates can complicate multi-center studies. The lack of universally accepted metrics for comparing sensitivity, effective resolution, transcript recovery and usable tissue area also creates uncertainty for customers evaluating competing technologies. Researchers must additionally manage very large image and molecular datasets while maintaining traceability from raw data to interpreted results. Translation into clinical decision-making will require stronger validation, reproducible operating procedures and evidence that spatial biomarkers provide value beyond conventional pathology and sequencing approaches.

Industry Chain Analysis

The upstream portion of the Spatial Transcriptomics Sequencing industry chain comprises tissue slides and capture substrates, spatial barcodes, oligonucleotide probes, enzymes, antibodies, staining reagents, library-preparation materials, sequencing consumables, imaging components and laboratory automation equipment. It also includes sequencers, high-resolution microscopes, fluidic systems, scanners, servers, cloud-computing resources and software infrastructure. Upstream performance directly influences RNA recovery, optical quality, spatial fidelity, assay reproducibility and usable tissue area. Sample-specific requirements create close interaction among reagent developers, instrument manufacturers, pathology laboratories and sequencing technology providers.

The midstream segment includes spatial platform developers, sequencing-system suppliers and specialized service laboratories that convert tissue samples into spatially resolved expression datasets. Their activities cover sample acceptance, pathology review, tissue optimization, molecular processing, library construction, sequencing or imaging, primary data processing, cell segmentation, spatial clustering and visualization. Downstream users include universities, research institutes, hospitals, pharmaceutical companies, biotechnology enterprises and contract research organizations. Value creation is concentrated in robust sample preparation, dependable molecular sensitivity, resolution, throughput, bioinformatics capability and accurate biological interpretation. Major costs include proprietary reagents, tissue processing, instrument depreciation, sequencing, image acquisition, data storage, computation and specialist labor. Platform suppliers generate value through instruments, consumables and software, while service providers compete through workflow breadth, project experience, turnaround time and analytical support.

Segment Insights

NGS-Based Capture Spatial Transcriptomics is positioned around broad gene-expression discovery and generally integrates tissue imaging with spatially indexed RNA capture, library preparation and next-generation sequencing. Its principal advantage is the ability to profile a large portion of the transcriptome without restricting the experiment to a narrowly predefined gene panel. Denser capture arrays and improved computational binning are enabling increasingly detailed analysis approaching cellular scale, while high-throughput sequencers support expansion into larger tissue areas and sample cohorts. The segment is particularly suitable for discovery research, tissue atlasing and projects in which unexpected pathways or cell states may be important. Its operational requirements include sequencing capacity, substantial data processing and careful coordination between histology and molecular workflows.

In Situ Sequencing-Based Spatial Transcriptomics and related imaging-based approaches measure transcripts within intact tissue through multiplexed cycles of hybridization, imaging or local molecular identification. These technologies provide strong single-cell and subcellular localization, allowing researchers to examine cell boundaries, intracellular transcript distribution and interactions between neighboring cell populations. Targeted panels can offer high sensitivity for selected genes and efficient hypothesis-driven studies, while newer systems are expanding toward substantially broader transcript coverage. The Others segment includes region-of-interest profiling, alternative bead- or array-based capture methods and specialized workflows combining spatial transcriptomics with other molecular measurements. The competitive boundary among segments is becoming less rigid as sequencing-based products improve resolution and imaging-based systems expand gene coverage and tissue throughput.

Downstream Market Opportunities

Cancer Research provides a major downstream opportunity because Spatial Transcriptomics Sequencing can distinguish tumor, stromal and immune compartments while preserving their physical relationships. This supports investigation of intratumoral heterogeneity, immune exclusion, metastatic niches, drug-response mechanisms and candidate spatial biomarkers. Developmental Biology benefits from the ability to reconstruct where cell states emerge and how organs are organized over time, creating opportunities in embryology, regenerative research, organoids and comparative biology. Neuroscience applications use spatial expression maps to classify cell populations across brain regions, connect molecular identity with anatomy and investigate neurological disease. The Other category includes immunology, infectious diseases, cardiovascular research, metabolic disease, fibrosis, tissue engineering and pharmaceutical development. Across these applications, the strongest commercial opportunities arise when technology providers and service laboratories can support complex sample types, provide reliable pathology integration and convert high-dimensional spatial data into interpretable biological conclusions.

Regional Insights

North America represents the most mature commercialization ecosystem for Spatial Transcriptomics Sequencing, supported by a concentration of platform developers, sequencing technology companies, biomedical research institutions, pharmaceutical enterprises and specialist service providers. The region has broad adoption across Cancer Research, translational medicine and neuroscience, and customers can access both instrument-based workflows and outsourced end-to-end services. Continued product launches in sequencing-based and imaging-based spatial systems are expanding competition across resolution, transcript coverage, sample compatibility and analytical software. Europe also has significant capabilities in molecular imaging, in situ analysis, pathology research and pharmaceutical development, with regional demand shaped by academic research networks and translational projects using preserved clinical tissue.

Asia-Pacific has become an important innovation and service-delivery region. China combines domestic spatial technology development with an extensive genomics-service infrastructure, while Japan has established sequencing, biomedical research and clinical-sample processing capabilities. Regional suppliers increasingly offer multiple technical routes rather than a single assay, allowing customers to select workflows according to tissue type, resolution, transcript coverage and research budget. Large population cohorts, active cancer and neuroscience research, and expanding pharmaceutical research create a foundation for future demand. However, adoption varies by country because advanced instruments, specialist pathology resources, computational capacity and research funding remain unevenly distributed.

Competitive Landscape Analysis

The Spatial Transcriptomics Sequencing market has a layered competitive structure comprising platform developers, sequencing infrastructure providers and outsourced multiomics service companies. 10x Genomics, Inc. has established a strong position in NGS-Based Capture Spatial Transcriptomics through its spatially barcoded whole-transcriptome workflows, while Bruker Spatial Biology and Vizgen, Inc. compete in high-plex imaging and cellular or subcellular spatial analysis. Illumina, Inc. is extending its sequencing ecosystem into an end-to-end spatial solution, increasing competition around whole-transcriptome breadth, spatial resolution and workflow scalability. STOmics (BGI Spatial), Resolve Biosciences GmbH and Curio Bioscience, Inc. provide differentiated spatial architectures based on large-area capture, in situ molecular mapping or sequencing-compatible spatial arrays. Takara Bio Inc. participates through its broader molecular biology and sequencing workflow capabilities. Novogene Co., Ltd., Biomarker Technologies Corporation, LC-Bio Technology Co., Ltd., Majorbio Bio-Pharm Technology Co., Ltd., Shanghai Biotechnology Corporation, Annoroad Gene Technology (Beijing) Co., Ltd., OE Biotech Co., Ltd., NovelBio Bio-Pharm Technology Co., Ltd., OBiO Technology (Shanghai) Corp., Ltd. and Shanghai Jingzhou Gene Technology Co., Ltd. (Sinomics) represent China’s broad sequencing and life-science service base, where competition centers on platform access, sample-processing experience, bioinformatics and integrated project delivery. RIKEN GENESIS Co., Ltd. and Rhelixa, Inc. support the Japanese service market through genomics analysis and project execution. Competitive advantage depends on technology performance, installed workflow accessibility, reagent continuity, tissue-type coverage, data-analysis quality, application support and the capacity to convert complex assays into reproducible services.

Report Scope

This report studies the global Spatial Transcriptomics Sequencing demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Spatial Transcriptomics Sequencing, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Spatial Transcriptomics Sequencing that contribute to its increasing demand across many markets.

Highlights and key features of the study

• Global Spatial Transcriptomics Sequencing total market, 2021-2032, (USD Million)
• Global Spatial Transcriptomics Sequencing total market by region & country, CAGR, 2021-2032, (USD Million)
• U.S. VS China: Spatial Transcriptomics Sequencing total market, key domestic companies, and share, (USD Million)
• Global Spatial Transcriptomics Sequencing revenue by player, revenue and market share 2021-2026, (USD Million)
• Global Spatial Transcriptomics Sequencing total market by Type, CAGR, 2021-2032, (USD Million)
• Global Spatial Transcriptomics Sequencing total market by Application, CAGR, 2021-2032, (USD Million)

This report profiles major players in the global Spatial Transcriptomics Sequencing market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include 10x Genomics, Inc., Bruker Spatial Biology, Illumina, Inc., Novogene Co., Ltd., STOmics (BGI Spatial), Vizgen, Inc., Takara Bio Inc., Biomarker Technologies Corporation, LC-Bio Technology Co., Ltd., Majorbio Bio-Pharm Technology Co., Ltd., etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Spatial Transcriptomics Sequencing market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Spatial Transcriptomics Sequencing Market, By Region:

• United States
• China
• Europe
• Japan
• South Korea
• ASEAN
• India
• Rest of World

Market Segmentation

Global Spatial Transcriptomics Sequencing Market, Segmentation by Type:

• NGS-Based Capture Spatial Transcriptomics
• In Situ Sequencing-Based Spatial Transcriptomics
• Others

Global Spatial Transcriptomics Sequencing Market, Segmentation by Transcript Coverage:

• Whole-Transcriptome Spatial Profiling
• Targeted High-Plex Spatial Profiling
• Custom Gene-Panel Spatial Profiling

Global Spatial Transcriptomics Sequencing Market, Segmentation by Spatial Spot Diameter:

• Low Resolution Platform: Spot Diameter > 100 μm
• Medium Resolution Platform: Spot Diameter 10 μm – 100 μm
• Single-Cell High Resolution Platform: Spot Diameter < 10 μm

Global Spatial Transcriptomics Sequencing Market, Segmentation by Application:

• Cancer Research
• Developmental Biology
• Neuroscience
• Other

Companies Profiled:

• 10x Genomics, Inc.
• Bruker Spatial Biology
• Illumina, Inc.
• Novogene Co., Ltd.
• STOmics (BGI Spatial)
• Vizgen, Inc.
• Takara Bio Inc.
• Biomarker Technologies Corporation
• LC-Bio Technology Co., Ltd.
• Majorbio Bio-Pharm Technology Co., Ltd.
• Shanghai Biotechnology Corporation
• Resolve Biosciences GmbH
• Curio Bioscience, Inc.
• Annoroad Gene Technology (Beijing) Co., Ltd.
• OE Biotech Co., Ltd.
• NovelBio Bio-Pharm Technology Co., Ltd.
• OBiO Technology (Shanghai) Corp., Ltd.
• Shanghai Jingzhou Gene Technology Co., Ltd. (Sinomics)
• RIKEN GENESIS Co., Ltd.
• Rhelixa, Inc.

Key Questions Answered

1. How big is the global Spatial Transcriptomics Sequencing market?
2. What is the demand of the global Spatial Transcriptomics Sequencing market?
3. What is the year over year growth of the global Spatial Transcriptomics Sequencing market?
4. What is the total value of the global Spatial Transcriptomics Sequencing market?
5. Who are the Major Players in the global Spatial Transcriptomics Sequencing market?
6. What are the growth factors driving the market demand?

Contents

1 SUPPLY SUMMARY

1.1 Spatial Transcriptomics Sequencing Introduction
1.2 World Spatial Transcriptomics Sequencing Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Spatial Transcriptomics Sequencing Total Market by Region (by Headquarter Location)
  1.3.1 World Spatial Transcriptomics Sequencing Market Size by Region (2021-2032), (by Headquarter Location)
  1.3.2 United States Based Company Spatial Transcriptomics Sequencing Revenue (2021-2032)
  1.3.3 China Based Company Spatial Transcriptomics Sequencing Revenue (2021-2032)
  1.3.4 Europe Based Company Spatial Transcriptomics Sequencing Revenue (2021-2032)
  1.3.5 Japan Based Company Spatial Transcriptomics Sequencing Revenue (2021-2032)
  1.3.6 South Korea Based Company Spatial Transcriptomics Sequencing Revenue (2021-2032)
  1.3.7 ASEAN Based Company Spatial Transcriptomics Sequencing Revenue (2021-2032)
  1.3.8 India Based Company Spatial Transcriptomics Sequencing Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
  1.4.1 Spatial Transcriptomics Sequencing Market Drivers
  1.4.2 Factors Affecting Demand
  1.4.3 Major Market Trends

2 DEMAND SUMMARY

2.1 World Spatial Transcriptomics Sequencing Consumption Value (2021-2032)
2.2 World Spatial Transcriptomics Sequencing Consumption Value by Region
  2.2.1 World Spatial Transcriptomics Sequencing Consumption Value by Region (2021-2026)
  2.2.2 World Spatial Transcriptomics Sequencing Consumption Value Forecast by Region (2027-2032)
2.3 United States Spatial Transcriptomics Sequencing Consumption Value (2021-2032)
2.4 China Spatial Transcriptomics Sequencing Consumption Value (2021-2032)
2.5 Europe Spatial Transcriptomics Sequencing Consumption Value (2021-2032)
2.6 Japan Spatial Transcriptomics Sequencing Consumption Value (2021-2032)
2.7 South Korea Spatial Transcriptomics Sequencing Consumption Value (2021-2032)
2.8 ASEAN Spatial Transcriptomics Sequencing Consumption Value (2021-2032)
2.9 India Spatial Transcriptomics Sequencing Consumption Value (2021-2032)

3 WORLD SPATIAL TRANSCRIPTOMICS SEQUENCING COMPANIES COMPETITIVE ANALYSIS

3.1 World Spatial Transcriptomics Sequencing Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
  3.2.1 Global Spatial Transcriptomics Sequencing Industry Rank of Major Players
  3.2.2 Global Concentration Ratios (CR4) for Spatial Transcriptomics Sequencing in 2025
  3.2.3 Global Concentration Ratios (CR8) for Spatial Transcriptomics Sequencing in 2025
3.3 Spatial Transcriptomics Sequencing Company Evaluation Quadrant
3.4 Spatial Transcriptomics Sequencing Market: Overall Company Footprint Analysis
  3.4.1 Spatial Transcriptomics Sequencing Market: Region Footprint
  3.4.2 Spatial Transcriptomics Sequencing Market: Company Product Type Footprint
  3.4.3 Spatial Transcriptomics Sequencing Market: Company Product Application Footprint
3.5 Competitive Environment
  3.5.1 Historical Structure of the Industry
  3.5.2 Barriers of Market Entry
  3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)

4.1 United States VS China: Spatial Transcriptomics Sequencing Revenue Comparison (by Headquarter Location)
  4.1.1 United States VS China: Spatial Transcriptomics Sequencing Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
  4.1.2 United States VS China: Spatial Transcriptomics Sequencing Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Spatial Transcriptomics Sequencing Consumption Value Comparison
  4.2.1 United States VS China: Spatial Transcriptomics Sequencing Consumption Value Comparison (2021 & 2025 & 2032)
  4.2.2 United States VS China: Spatial Transcriptomics Sequencing Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Spatial Transcriptomics Sequencing Companies and Market Share, 2021-2026
  4.3.1 United States Based Spatial Transcriptomics Sequencing Companies, Headquarters (States, Country)
  4.3.2 United States Based Companies Spatial Transcriptomics Sequencing Revenue, (2021-2026)
4.4 China Based Companies Spatial Transcriptomics Sequencing Revenue and Market Share, 2021-2026
  4.4.1 China Based Spatial Transcriptomics Sequencing Companies, Company Headquarters (Province, Country)
  4.4.2 China Based Companies Spatial Transcriptomics Sequencing Revenue, (2021-2026)
4.5 Rest of World Based Spatial Transcriptomics Sequencing Companies and Market Share, 2021-2026
  4.5.1 Rest of World Based Spatial Transcriptomics Sequencing Companies, Headquarters (Province, Country)
  4.5.2 Rest of World Based Companies Spatial Transcriptomics Sequencing Revenue (2021-2026)

5 MARKET ANALYSIS BY TYPE

5.1 World Spatial Transcriptomics Sequencing Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
  5.2.1 NGS-Based Capture Spatial Transcriptomics
  5.2.2 In Situ Sequencing-Based Spatial Transcriptomics
  5.2.3 Others
5.3 Market Segment by Type
  5.3.1 World Spatial Transcriptomics Sequencing Market Size by Type (2021-2026)
  5.3.2 World Spatial Transcriptomics Sequencing Market Size by Type (2027-2032)
  5.3.3 World Spatial Transcriptomics Sequencing Market Size Market Share by Type (2027-2032)

6 MARKET ANALYSIS BY TRANSCRIPT COVERAGE

6.1 World Spatial Transcriptomics Sequencing Market Size Overview by Transcript Coverage: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Transcript Coverage
  6.2.1 Whole-Transcriptome Spatial Profiling
  6.2.2 Targeted High-Plex Spatial Profiling
  6.2.3 Custom Gene-Panel Spatial Profiling
6.3 Market Segment by Transcript Coverage
  6.3.1 World Spatial Transcriptomics Sequencing Market Size by Transcript Coverage (2021-2026)
  6.3.2 World Spatial Transcriptomics Sequencing Market Size by Transcript Coverage (2027-2032)
  6.3.3 World Spatial Transcriptomics Sequencing Market Size Market Share by Transcript Coverage (2027-2032)

7 MARKET ANALYSIS BY SPATIAL SPOT DIAMETER

7.1 World Spatial Transcriptomics Sequencing Market Size Overview by Spatial Spot Diameter: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Spatial Spot Diameter
  7.2.1 Low Resolution Platform: Spot Diameter > 100 μm
  7.2.2 Medium Resolution Platform: Spot Diameter 10 μm – 100 μm
  7.2.3 Single-Cell High Resolution Platform: Spot Diameter < 10 μm
7.3 Market Segment by Spatial Spot Diameter
  7.3.1 World Spatial Transcriptomics Sequencing Market Size by Spatial Spot Diameter (2021-2026)
  7.3.2 World Spatial Transcriptomics Sequencing Market Size by Spatial Spot Diameter (2027-2032)
  7.3.3 World Spatial Transcriptomics Sequencing Market Size Market Share by Spatial Spot Diameter (2027-2032)

8 MARKET ANALYSIS BY APPLICATION

8.1 World Spatial Transcriptomics Sequencing Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
  8.2.1 Cancer Research
  8.2.2 Developmental Biology
  8.2.3 Neuroscience
  8.2.4 Other
8.3 Market Segment by Application
  8.3.1 World Spatial Transcriptomics Sequencing Market Size by Application (2021-2026)
  8.3.2 World Spatial Transcriptomics Sequencing Market Size by Application (2027-2032)
  8.3.3 World Spatial Transcriptomics Sequencing Market Size Market Share by Application (2021-2032)

9 COMPANY PROFILES

9.1 10x Genomics, Inc.
  9.1.1 10x Genomics, Inc. Details
  9.1.2 10x Genomics, Inc. Major Business
  9.1.3 10x Genomics, Inc. Spatial Transcriptomics Sequencing Product and Services
  9.1.4 10x Genomics, Inc. Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026)
  9.1.5 10x Genomics, Inc. Recent Developments/Updates
  9.1.6 10x Genomics, Inc. Competitive Strengths & Weaknesses
9.2 Bruker Spatial Biology
  9.2.1 Bruker Spatial Biology Details
  9.2.2 Bruker Spatial Biology Major Business
  9.2.3 Bruker Spatial Biology Spatial Transcriptomics Sequencing Product and Services
  9.2.4 Bruker Spatial Biology Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026)
  9.2.5 Bruker Spatial Biology Recent Developments/Updates
  9.2.6 Bruker Spatial Biology Competitive Strengths & Weaknesses
9.3 Illumina, Inc.
  9.3.1 Illumina, Inc. Details
  9.3.2 Illumina, Inc. Major Business
  9.3.3 Illumina, Inc. Spatial Transcriptomics Sequencing Product and Services
  9.3.4 Illumina, Inc. Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026)
  9.3.5 Illumina, Inc. Recent Developments/Updates
  9.3.6 Illumina, Inc. Competitive Strengths & Weaknesses
9.4 Novogene Co., Ltd.
  9.4.1 Novogene Co., Ltd. Details
  9.4.2 Novogene Co., Ltd. Major Business
  9.4.3 Novogene Co., Ltd. Spatial Transcriptomics Sequencing Product and Services
  9.4.4 Novogene Co., Ltd. Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026)
  9.4.5 Novogene Co., Ltd. Recent Developments/Updates
  9.4.6 Novogene Co., Ltd. Competitive Strengths & Weaknesses
9.5 STOmics (BGI Spatial)
  9.5.1 STOmics (BGI Spatial) Details
  9.5.2 STOmics (BGI Spatial) Major Business
  9.5.3 STOmics (BGI Spatial) Spatial Transcriptomics Sequencing Product and Services
  9.5.4 STOmics (BGI Spatial) Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026)
  9.5.5 STOmics (BGI Spatial) Recent Developments/Updates
  9.5.6 STOmics (BGI Spatial) Competitive Strengths & Weaknesses
9.6 Vizgen, Inc.
  9.6.1 Vizgen, Inc. Details
  9.6.2 Vizgen, Inc. Major Business
  9.6.3 Vizgen, Inc. Spatial Transcriptomics Sequencing Product and Services
  9.6.4 Vizgen, Inc. Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026)
  9.6.5 Vizgen, Inc. Recent Developments/Updates
  9.6.6 Vizgen, Inc. Competitive Strengths & Weaknesses
9.7 Takara Bio Inc.
  9.7.1 Takara Bio Inc. Details
  9.7.2 Takara Bio Inc. Major Business
  9.7.3 Takara Bio Inc. Spatial Transcriptomics Sequencing Product and Services
  9.7.4 Takara Bio Inc. Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026)
  9.7.5 Takara Bio Inc. Recent Developments/Updates
  9.7.6 Takara Bio Inc. Competitive Strengths & Weaknesses
9.8 Biomarker Technologies Corporation
  9.8.1 Biomarker Technologies Corporation Details
  9.8.2 Biomarker Technologies Corporation Major Business
  9.8.3 Biomarker Technologies Corporation Spatial Transcriptomics Sequencing Product and Services
  9.8.4 Biomarker Technologies Corporation Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026)
  9.8.5 Biomarker Technologies Corporation Recent Developments/Updates
  9.8.6 Biomarker Technologies Corporation Competitive Strengths & Weaknesses
9.9 LC-Bio Technology Co., Ltd.
  9.9.1 LC-Bio Technology Co., Ltd. Details
  9.9.2 LC-Bio Technology Co., Ltd. Major Business
  9.9.3 LC-Bio Technology Co., Ltd. Spatial Transcriptomics Sequencing Product and Services
  9.9.4 LC-Bio Technology Co., Ltd. Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026)
  9.9.5 LC-Bio Technology Co., Ltd. Recent Developments/Updates
  9.9.6 LC-Bio Technology Co., Ltd. Competitive Strengths & Weaknesses
9.10 Majorbio Bio-Pharm Technology Co., Ltd.
  9.10.1 Majorbio Bio-Pharm Technology Co., Ltd. Details
  9.10.2 Majorbio Bio-Pharm Technology Co., Ltd. Major Business
  9.10.3 Majorbio Bio-Pharm Technology Co., Ltd. Spatial Transcriptomics Sequencing Product and Services
  9.10.4 Majorbio Bio-Pharm Technology Co., Ltd. Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026)
  9.10.5 Majorbio Bio-Pharm Technology Co., Ltd. Recent Developments/Updates
  9.10.6 Majorbio Bio-Pharm Technology Co., Ltd. Competitive Strengths & Weaknesses
9.11 Shanghai Biotechnology Corporation
  9.11.1 Shanghai Biotechnology Corporation Details
  9.11.2 Shanghai Biotechnology Corporation Major Business
  9.11.3 Shanghai Biotechnology Corporation Spatial Transcriptomics Sequencing Product and Services
  9.11.4 Shanghai Biotechnology Corporation Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026)
  9.11.5 Shanghai Biotechnology Corporation Recent Developments/Updates
  9.11.6 Shanghai Biotechnology Corporation Competitive Strengths & Weaknesses
9.12 Resolve Biosciences GmbH
  9.12.1 Resolve Biosciences GmbH Details
  9.12.2 Resolve Biosciences GmbH Major Business
  9.12.3 Resolve Biosciences GmbH Spatial Transcriptomics Sequencing Product and Services
  9.12.4 Resolve Biosciences GmbH Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026)
  9.12.5 Resolve Biosciences GmbH Recent Developments/Updates
  9.12.6 Resolve Biosciences GmbH Competitive Strengths & Weaknesses
9.13 Curio Bioscience, Inc.
  9.13.1 Curio Bioscience, Inc. Details
  9.13.2 Curio Bioscience, Inc. Major Business
  9.13.3 Curio Bioscience, Inc. Spatial Transcriptomics Sequencing Product and Services
  9.13.4 Curio Bioscience, Inc. Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026)
  9.13.5 Curio Bioscience, Inc. Recent Developments/Updates
  9.13.6 Curio Bioscience, Inc. Competitive Strengths & Weaknesses
9.14 Annoroad Gene Technology (Beijing) Co., Ltd.
  9.14.1 Annoroad Gene Technology (Beijing) Co., Ltd. Details
  9.14.2 Annoroad Gene Technology (Beijing) Co., Ltd. Major Business
  9.14.3 Annoroad Gene Technology (Beijing) Co., Ltd. Spatial Transcriptomics Sequencing Product and Services
  9.14.4 Annoroad Gene Technology (Beijing) Co., Ltd. Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026)
  9.14.5 Annoroad Gene Technology (Beijing) Co., Ltd. Recent Developments/Updates
  9.14.6 Annoroad Gene Technology (Beijing) Co., Ltd. Competitive Strengths & Weaknesses
9.15 OE Biotech Co., Ltd.
  9.15.1 OE Biotech Co., Ltd. Details
  9.15.2 OE Biotech Co., Ltd. Major Business
  9.15.3 OE Biotech Co., Ltd. Spatial Transcriptomics Sequencing Product and Services
  9.15.4 OE Biotech Co., Ltd. Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026)
  9.15.5 OE Biotech Co., Ltd. Recent Developments/Updates
  9.15.6 OE Biotech Co., Ltd. Competitive Strengths & Weaknesses
9.16 NovelBio Bio-Pharm Technology Co., Ltd.
  9.16.1 NovelBio Bio-Pharm Technology Co., Ltd. Details
  9.16.2 NovelBio Bio-Pharm Technology Co., Ltd. Major Business
  9.16.3 NovelBio Bio-Pharm Technology Co., Ltd. Spatial Transcriptomics Sequencing Product and Services
  9.16.4 NovelBio Bio-Pharm Technology Co., Ltd. Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026)
  9.16.5 NovelBio Bio-Pharm Technology Co., Ltd. Recent Developments/Updates
  9.16.6 NovelBio Bio-Pharm Technology Co., Ltd. Competitive Strengths & Weaknesses
9.17 OBiO Technology (Shanghai) Corp., Ltd.
  9.17.1 OBiO Technology (Shanghai) Corp., Ltd. Details
  9.17.2 OBiO Technology (Shanghai) Corp., Ltd. Major Business
  9.17.3 OBiO Technology (Shanghai) Corp., Ltd. Spatial Transcriptomics Sequencing Product and Services
  9.17.4 OBiO Technology (Shanghai) Corp., Ltd. Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026)
  9.17.5 OBiO Technology (Shanghai) Corp., Ltd. Recent Developments/Updates
  9.17.6 OBiO Technology (Shanghai) Corp., Ltd. Competitive Strengths & Weaknesses
9.18 Shanghai Jingzhou Gene Technology Co., Ltd. (Sinomics)
  9.18.1 Shanghai Jingzhou Gene Technology Co., Ltd. (Sinomics) Details
  9.18.2 Shanghai Jingzhou Gene Technology Co., Ltd. (Sinomics) Major Business
  9.18.3 Shanghai Jingzhou Gene Technology Co., Ltd. (Sinomics) Spatial Transcriptomics Sequencing Product and Services
  9.18.4 Shanghai Jingzhou Gene Technology Co., Ltd. (Sinomics) Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026)
  9.18.5 Shanghai Jingzhou Gene Technology Co., Ltd. (Sinomics) Recent Developments/Updates
  9.18.6 Shanghai Jingzhou Gene Technology Co., Ltd. (Sinomics) Competitive Strengths & Weaknesses
9.19 RIKEN GENESIS Co., Ltd.
  9.19.1 RIKEN GENESIS Co., Ltd. Details
  9.19.2 RIKEN GENESIS Co., Ltd. Major Business
  9.19.3 RIKEN GENESIS Co., Ltd. Spatial Transcriptomics Sequencing Product and Services
  9.19.4 RIKEN GENESIS Co., Ltd. Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026)
  9.19.5 RIKEN GENESIS Co., Ltd. Recent Developments/Updates
  9.19.6 RIKEN GENESIS Co., Ltd. Competitive Strengths & Weaknesses
9.20 Rhelixa, Inc.
  9.20.1 Rhelixa, Inc. Details
  9.20.2 Rhelixa, Inc. Major Business
  9.20.3 Rhelixa, Inc. Spatial Transcriptomics Sequencing Product and Services
  9.20.4 Rhelixa, Inc. Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026)
  9.20.5 Rhelixa, Inc. Recent Developments/Updates
  9.20.6 Rhelixa, Inc. Competitive Strengths & Weaknesses

10 INDUSTRY CHAIN ANALYSIS

10.1 Spatial Transcriptomics Sequencing Industry Chain
10.2 Spatial Transcriptomics Sequencing Upstream Analysis
10.3 Spatial Transcriptomics Sequencing Midstream Analysis
10.4 Spatial Transcriptomics Sequencing Downstream Analysis

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX

12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. World Spatial Transcriptomics Sequencing Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Spatial Transcriptomics Sequencing Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Spatial Transcriptomics Sequencing Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Spatial Transcriptomics Sequencing Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Spatial Transcriptomics Sequencing Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Spatial Transcriptomics Sequencing Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Spatial Transcriptomics Sequencing Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Spatial Transcriptomics Sequencing Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Spatial Transcriptomics Sequencing Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Spatial Transcriptomics Sequencing Players in 2025
Table 12. World Spatial Transcriptomics Sequencing Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Spatial Transcriptomics Sequencing Company Evaluation Quadrant
Table 14. Head Office of Key Spatial Transcriptomics Sequencing Players
Table 15. Spatial Transcriptomics Sequencing Market: Company Product Type Footprint
Table 16. Spatial Transcriptomics Sequencing Market: Company Product Application Footprint
Table 17. Spatial Transcriptomics Sequencing Mergers & Acquisitions Activity
Table 18. United States VS China Spatial Transcriptomics Sequencing Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Spatial Transcriptomics Sequencing Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Spatial Transcriptomics Sequencing Companies, Headquarters (States, Country)
Table 21. United States Based Companies Spatial Transcriptomics Sequencing Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Spatial Transcriptomics Sequencing Revenue Market Share (2021-2026)
Table 23. China Based Spatial Transcriptomics Sequencing Companies, Headquarters (Province, Country)
Table 24. China Based Companies Spatial Transcriptomics Sequencing Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Spatial Transcriptomics Sequencing Revenue Market Share (2021-2026)
Table 26. Rest of World Based Spatial Transcriptomics Sequencing Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Spatial Transcriptomics Sequencing Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Spatial Transcriptomics Sequencing Revenue Market Share (2021-2026)
Table 29. World Spatial Transcriptomics Sequencing Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Spatial Transcriptomics Sequencing Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Spatial Transcriptomics Sequencing Market Size by Type (2027-2032) & (USD Million)
Table 32. World Spatial Transcriptomics Sequencing Market Size by Transcript Coverage, (USD Million), 2021 & 2025 & 2032
Table 33. World Spatial Transcriptomics Sequencing Market Size Value by Transcript Coverage (2021-2026) & (USD Million)
Table 34. World Spatial Transcriptomics Sequencing Market Size by Transcript Coverage (2027-2032) & (USD Million)
Table 35. World Spatial Transcriptomics Sequencing Market Size by Spatial Spot Diameter, (USD Million), 2021 & 2025 & 2032
Table 36. World Spatial Transcriptomics Sequencing Market Size Value by Spatial Spot Diameter (2021-2026) & (USD Million)
Table 37. World Spatial Transcriptomics Sequencing Market Size by Spatial Spot Diameter (2027-2032) & (USD Million)
Table 38. World Spatial Transcriptomics Sequencing Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Spatial Transcriptomics Sequencing Market Size by Application (2021-2026) & (USD Million)
Table 40. World Spatial Transcriptomics Sequencing Market Size by Application (2027-2032) & (USD Million)
Table 41. 10x Genomics, Inc. Basic Information, Manufacturing Base and Competitors
Table 42. 10x Genomics, Inc. Major Business
Table 43. 10x Genomics, Inc. Spatial Transcriptomics Sequencing Product and Services
Table 44. 10x Genomics, Inc. Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. 10x Genomics, Inc. Recent Developments/Updates
Table 46. 10x Genomics, Inc. Competitive Strengths & Weaknesses
Table 47. Bruker Spatial Biology Basic Information, Manufacturing Base and Competitors
Table 48. Bruker Spatial Biology Major Business
Table 49. Bruker Spatial Biology Spatial Transcriptomics Sequencing Product and Services
Table 50. Bruker Spatial Biology Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Bruker Spatial Biology Recent Developments/Updates
Table 52. Bruker Spatial Biology Competitive Strengths & Weaknesses
Table 53. Illumina, Inc. Basic Information, Manufacturing Base and Competitors
Table 54. Illumina, Inc. Major Business
Table 55. Illumina, Inc. Spatial Transcriptomics Sequencing Product and Services
Table 56. Illumina, Inc. Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Illumina, Inc. Recent Developments/Updates
Table 58. Illumina, Inc. Competitive Strengths & Weaknesses
Table 59. Novogene Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 60. Novogene Co., Ltd. Major Business
Table 61. Novogene Co., Ltd. Spatial Transcriptomics Sequencing Product and Services
Table 62. Novogene Co., Ltd. Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Novogene Co., Ltd. Recent Developments/Updates
Table 64. Novogene Co., Ltd. Competitive Strengths & Weaknesses
Table 65. STOmics (BGI Spatial) Basic Information, Manufacturing Base and Competitors
Table 66. STOmics (BGI Spatial) Major Business
Table 67. STOmics (BGI Spatial) Spatial Transcriptomics Sequencing Product and Services
Table 68. STOmics (BGI Spatial) Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. STOmics (BGI Spatial) Recent Developments/Updates
Table 70. STOmics (BGI Spatial) Competitive Strengths & Weaknesses
Table 71. Vizgen, Inc. Basic Information, Manufacturing Base and Competitors
Table 72. Vizgen, Inc. Major Business
Table 73. Vizgen, Inc. Spatial Transcriptomics Sequencing Product and Services
Table 74. Vizgen, Inc. Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Vizgen, Inc. Recent Developments/Updates
Table 76. Vizgen, Inc. Competitive Strengths & Weaknesses
Table 77. Takara Bio Inc. Basic Information, Manufacturing Base and Competitors
Table 78. Takara Bio Inc. Major Business
Table 79. Takara Bio Inc. Spatial Transcriptomics Sequencing Product and Services
Table 80. Takara Bio Inc. Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Takara Bio Inc. Recent Developments/Updates
Table 82. Takara Bio Inc. Competitive Strengths & Weaknesses
Table 83. Biomarker Technologies Corporation Basic Information, Manufacturing Base and Competitors
Table 84. Biomarker Technologies Corporation Major Business
Table 85. Biomarker Technologies Corporation Spatial Transcriptomics Sequencing Product and Services
Table 86. Biomarker Technologies Corporation Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Biomarker Technologies Corporation Recent Developments/Updates
Table 88. Biomarker Technologies Corporation Competitive Strengths & Weaknesses
Table 89. LC-Bio Technology Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 90. LC-Bio Technology Co., Ltd. Major Business
Table 91. LC-Bio Technology Co., Ltd. Spatial Transcriptomics Sequencing Product and Services
Table 92. LC-Bio Technology Co., Ltd. Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. LC-Bio Technology Co., Ltd. Recent Developments/Updates
Table 94. LC-Bio Technology Co., Ltd. Competitive Strengths & Weaknesses
Table 95. Majorbio Bio-Pharm Technology Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 96. Majorbio Bio-Pharm Technology Co., Ltd. Major Business
Table 97. Majorbio Bio-Pharm Technology Co., Ltd. Spatial Transcriptomics Sequencing Product and Services
Table 98. Majorbio Bio-Pharm Technology Co., Ltd. Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. Majorbio Bio-Pharm Technology Co., Ltd. Recent Developments/Updates
Table 100. Majorbio Bio-Pharm Technology Co., Ltd. Competitive Strengths & Weaknesses
Table 101. Shanghai Biotechnology Corporation Basic Information, Manufacturing Base and Competitors
Table 102. Shanghai Biotechnology Corporation Major Business
Table 103. Shanghai Biotechnology Corporation Spatial Transcriptomics Sequencing Product and Services
Table 104. Shanghai Biotechnology Corporation Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. Shanghai Biotechnology Corporation Recent Developments/Updates
Table 106. Shanghai Biotechnology Corporation Competitive Strengths & Weaknesses
Table 107. Resolve Biosciences GmbH Basic Information, Manufacturing Base and Competitors
Table 108. Resolve Biosciences GmbH Major Business
Table 109. Resolve Biosciences GmbH Spatial Transcriptomics Sequencing Product and Services
Table 110. Resolve Biosciences GmbH Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. Resolve Biosciences GmbH Recent Developments/Updates
Table 112. Resolve Biosciences GmbH Competitive Strengths & Weaknesses
Table 113. Curio Bioscience, Inc. Basic Information, Manufacturing Base and Competitors
Table 114. Curio Bioscience, Inc. Major Business
Table 115. Curio Bioscience, Inc. Spatial Transcriptomics Sequencing Product and Services
Table 116. Curio Bioscience, Inc. Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. Curio Bioscience, Inc. Recent Developments/Updates
Table 118. Curio Bioscience, Inc. Competitive Strengths & Weaknesses
Table 119. Annoroad Gene Technology (Beijing) Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 120. Annoroad Gene Technology (Beijing) Co., Ltd. Major Business
Table 121. Annoroad Gene Technology (Beijing) Co., Ltd. Spatial Transcriptomics Sequencing Product and Services
Table 122. Annoroad Gene Technology (Beijing) Co., Ltd. Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. Annoroad Gene Technology (Beijing) Co., Ltd. Recent Developments/Updates
Table 124. Annoroad Gene Technology (Beijing) Co., Ltd. Competitive Strengths & Weaknesses
Table 125. OE Biotech Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 126. OE Biotech Co., Ltd. Major Business
Table 127. OE Biotech Co., Ltd. Spatial Transcriptomics Sequencing Product and Services
Table 128. OE Biotech Co., Ltd. Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. OE Biotech Co., Ltd. Recent Developments/Updates
Table 130. OE Biotech Co., Ltd. Competitive Strengths & Weaknesses
Table 131. NovelBio Bio-Pharm Technology Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 132. NovelBio Bio-Pharm Technology Co., Ltd. Major Business
Table 133. NovelBio Bio-Pharm Technology Co., Ltd. Spatial Transcriptomics Sequencing Product and Services
Table 134. NovelBio Bio-Pharm Technology Co., Ltd. Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 135. NovelBio Bio-Pharm Technology Co., Ltd. Recent Developments/Updates
Table 136. NovelBio Bio-Pharm Technology Co., Ltd. Competitive Strengths & Weaknesses
Table 137. OBiO Technology (Shanghai) Corp., Ltd. Basic Information, Manufacturing Base and Competitors
Table 138. OBiO Technology (Shanghai) Corp., Ltd. Major Business
Table 139. OBiO Technology (Shanghai) Corp., Ltd. Spatial Transcriptomics Sequencing Product and Services
Table 140. OBiO Technology (Shanghai) Corp., Ltd. Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 141. OBiO Technology (Shanghai) Corp., Ltd. Recent Developments/Updates
Table 142. OBiO Technology (Shanghai) Corp., Ltd. Competitive Strengths & Weaknesses
Table 143. Shanghai Jingzhou Gene Technology Co., Ltd. (Sinomics) Basic Information, Manufacturing Base and Competitors
Table 144. Shanghai Jingzhou Gene Technology Co., Ltd. (Sinomics) Major Business
Table 145. Shanghai Jingzhou Gene Technology Co., Ltd. (Sinomics) Spatial Transcriptomics Sequencing Product and Services
Table 146. Shanghai Jingzhou Gene Technology Co., Ltd. (Sinomics) Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 147. Shanghai Jingzhou Gene Technology Co., Ltd. (Sinomics) Recent Developments/Updates
Table 148. Shanghai Jingzhou Gene Technology Co., Ltd. (Sinomics) Competitive Strengths & Weaknesses
Table 149. RIKEN GENESIS Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 150. RIKEN GENESIS Co., Ltd. Major Business
Table 151. RIKEN GENESIS Co., Ltd. Spatial Transcriptomics Sequencing Product and Services
Table 152. RIKEN GENESIS Co., Ltd. Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 153. RIKEN GENESIS Co., Ltd. Recent Developments/Updates
Table 154. RIKEN GENESIS Co., Ltd. Competitive Strengths & Weaknesses
Table 155. Rhelixa, Inc. Basic Information, Manufacturing Base and Competitors
Table 156. Rhelixa, Inc. Major Business
Table 157. Rhelixa, Inc. Spatial Transcriptomics Sequencing Product and Services
Table 158. Rhelixa, Inc. Spatial Transcriptomics Sequencing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 159. Rhelixa, Inc. Recent Developments/Updates
Table 160. Rhelixa, Inc. Competitive Strengths & Weaknesses
Table 161. Global Key Players of Spatial Transcriptomics Sequencing Upstream (Raw Materials)
Table 162. Global Spatial Transcriptomics Sequencing Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. Spatial Transcriptomics Sequencing Picture
Figure 2. World Spatial Transcriptomics Sequencing Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Spatial Transcriptomics Sequencing Total Revenue (2021-2032) & (USD Million)
Figure 4. World Spatial Transcriptomics Sequencing Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Spatial Transcriptomics Sequencing Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Spatial Transcriptomics Sequencing Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Spatial Transcriptomics Sequencing Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Spatial Transcriptomics Sequencing Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Spatial Transcriptomics Sequencing Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Spatial Transcriptomics Sequencing Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Spatial Transcriptomics Sequencing Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Spatial Transcriptomics Sequencing Revenue (2021-2032) & (USD Million)
Figure 13. Spatial Transcriptomics Sequencing Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Spatial Transcriptomics Sequencing Consumption Value (2021-2032) & (USD Million)
Figure 16. World Spatial Transcriptomics Sequencing Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Spatial Transcriptomics Sequencing Consumption Value (2021-2032) & (USD Million)
Figure 18. China Spatial Transcriptomics Sequencing Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Spatial Transcriptomics Sequencing Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Spatial Transcriptomics Sequencing Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Spatial Transcriptomics Sequencing Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Spatial Transcriptomics Sequencing Consumption Value (2021-2032) & (USD Million)
Figure 23. India Spatial Transcriptomics Sequencing Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Spatial Transcriptomics Sequencing by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Spatial Transcriptomics Sequencing Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Spatial Transcriptomics Sequencing Markets in 2025
Figure 27. United States VS China: Spatial Transcriptomics Sequencing Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Spatial Transcriptomics Sequencing Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Spatial Transcriptomics Sequencing Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Spatial Transcriptomics Sequencing Market Size Market Share by Type in 2025
Figure 31. NGS-Based Capture Spatial Transcriptomics
Figure 32. In Situ Sequencing-Based Spatial Transcriptomics
Figure 33. Others
Figure 34. World Spatial Transcriptomics Sequencing Market Size Market Share by Type (2021-2032)
Figure 35. World Spatial Transcriptomics Sequencing Market Size by Transcript Coverage, (USD Million), 2021 & 2025 & 2032
Figure 36. World Spatial Transcriptomics Sequencing Market Size Market Share by Transcript Coverage in 2025
Figure 37. Whole-Transcriptome Spatial Profiling
Figure 38. Targeted High-Plex Spatial Profiling
Figure 39. Custom Gene-Panel Spatial Profiling
Figure 40. World Spatial Transcriptomics Sequencing Market Size Market Share by Transcript Coverage (2021-2032)
Figure 41. World Spatial Transcriptomics Sequencing Market Size by Spatial Spot Diameter, (USD Million), 2021 & 2025 & 2032
Figure 42. World Spatial Transcriptomics Sequencing Market Size Market Share by Spatial Spot Diameter in 2025
Figure 43. Low Resolution Platform: Spot Diameter > 100 μm
Figure 44. Medium Resolution Platform: Spot Diameter 10 μm – 100 μm
Figure 45. Single-Cell High Resolution Platform: Spot Diameter < 10 μm
Figure 46. World Spatial Transcriptomics Sequencing Market Size Market Share by Spatial Spot Diameter (2021-2032)
Figure 47. World Spatial Transcriptomics Sequencing Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 48. World Spatial Transcriptomics Sequencing Market Size Market Share by Application in 2025
Figure 49. Cancer Research
Figure 50. Developmental Biology
Figure 51. Neuroscience
Figure 52. Other
Figure 53. World Spatial Transcriptomics Sequencing Market Size Market Share by Application (2021-2032)
Figure 54. Spatial Transcriptomics Sequencing Industrial Chain
Figure 55. Methodology
Figure 56. Research Process and Data Source